Diagnosis and treatment of chronic hepatitis B: 2009 update
- PMID: 19212304
Diagnosis and treatment of chronic hepatitis B: 2009 update
Abstract
The diagnosis of chronic hepatitis B (CHB) is made using a combination of serological, virologic, biochemical, and histologic markers. The natural history of hepatitis B virus (HBV) infection can be divided into four phases: immune tolerance, immune clearance (HBeAg-positive chronic hepatitis B), inactive HBsAg carrier, and reactivation (HBeAg-negative chronic hepatitis B). Patients in the immune clearance and reactivation phases, with elevated alanine aminotransferase (ALT) and HBV DNA levels, are candidates for antiviral therapy. The primary determinant of treatment outcomes for CHB is suppression of serum HBV DNA, and long-term suppression of viral replication is likely to reduce progression to cirrhosis and hepatocellular carcinoma. Current antiviral treatment options for CHB include interferon alfa-2b, peginterferon alfa-2a, lamivudine, adefovir, entecavir, telbivudine, and tenofovir. In patients with HBeAg-positive CHB, antiviral treatment is indicated when the serum HBV DNA level is 20 000 IU/mL and the ALT level is elevated. For HBeAg-negative patients, the threshold for initiation of therapy is lower, i.e., a serum HBV DNA level 2 000 IU/mL in association with an elevated ALT level. The presence of at least moderate necroinflammation and the presence of fibrosis on liver biopsy may be useful in supporting the decision to initiate therapy, particularly in patients with normal ALT levels. While undergoing therapy, patients require monitoring every 3 to 6 months to ensure adherence to therapy, confirm that the response to therapy is optimal, and survey for the development of resistance if an oral agent is used. Issues that remain controversial or need to be studied further are the necessity of a baseline liver biopsy, the HBV DNA and ALT thresholds for initiation of therapy, the optimal duration of antiviral therapy, selection of one agent over another, response to suboptimal suppression of viral replication, and the role of combination therapy.
Similar articles
-
Diagnosis and treatment of chronic hepatitis B: an update.Minerva Gastroenterol Dietol. 2007 Mar;53(1):25-41. Minerva Gastroenterol Dietol. 2007. PMID: 17415343 Review.
-
Diagnosis and treatment of chronic hepatitis B.Minerva Gastroenterol Dietol. 2004 Dec;50(4):289-303. Minerva Gastroenterol Dietol. 2004. PMID: 15788985 Review.
-
Treatment of chronic hepatitis B virus infection - Dutch national guidelines.Neth J Med. 2008 Jul-Aug;66(7):292-306. Neth J Med. 2008. PMID: 18663260 Review.
-
Therapeutic strategies for chronic hepatitis B virus infection in 2008.Am J Med. 2008 Dec;121(12 Suppl):S33-44. doi: 10.1016/j.amjmed.2008.09.027. Am J Med. 2008. PMID: 19185073
-
Management of chronic hepatitis B virus infection: a new era of disease control.Intern Med J. 2006 Feb;36(2):100-13. doi: 10.1111/j.1445-5994.2006.01027.x. Intern Med J. 2006. PMID: 16472264 Review.
Cited by
-
The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):281-6. doi: 10.1097/QAI.0000000000000857. J Acquir Immune Defic Syndr. 2016. PMID: 26413853 Free PMC article. Clinical Trial.
-
Treatment of rheumatic diseases and hepatitis B virus coinfection.Rheumatol Int. 2015 Mar;35(3):385-92. doi: 10.1007/s00296-014-3195-8. Epub 2014 Dec 31. Rheumatol Int. 2015. PMID: 25549599 Free PMC article. Review.
-
Overview of miR-106a Regulatory Roles: from Cancer to Aging.Bioengineering (Basel). 2023 Jul 27;10(8):892. doi: 10.3390/bioengineering10080892. Bioengineering (Basel). 2023. PMID: 37627777 Free PMC article. Review.
-
De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients.Hepatol Int. 2011 Jun;5(2):671-6. doi: 10.1007/s12072-010-9243-x. Epub 2011 Jan 19. Hepatol Int. 2011. PMID: 21484140 Free PMC article.
-
Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study.Med Sci Monit. 2013 Sep 9;19:751-6. doi: 10.12659/MSM.889443. Med Sci Monit. 2013. PMID: 24019010 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources